Skip to content
ClosedNo longer accepting applications

Olink Explorer >5400

HEALTH AND HUMAN SERVICES, DEPARTMENT OF

This opportunity closed July 25, 2026. 5 similar opportunities are open right now.

About this archived opportunity

Requirements: 2.0 BACKGROUND Our lab studies the role of inflammation/innate resistance and commensal microbiota in carcinogenesis, cancer progression and therapy of cancer. The following product features/characteristics are required for this requirement: Protein Coverage - Measures ~5,400+ human proteins simultaneously in a single workflow. Technology - Uses Proximity Extension Assay (PEA) with dual antibody recognition coupled to DNA barcoding and next-generation sequencing (NGS) readout. Sample input – requires only 2 ul of plasma, serum, and other sample types Specificity - Reported 99.5% specificity with negligible cross-reactivity due to dual-recognition antibody design. Dynamic Range - Approximately 10 orders of magnitude (fg/mL to mg/mL), enabling detection of both low- and high-abundance proteins. Key strengths Very broad proteome coverage while maintaining antibody-based specificity. Excellent sensitivity for low-abundance circulating proteins (especially cytokines and signaling proteins). Extremely low sample-volume requirement. Highly standardized platform, making it attractive for epidemiology and multi-omics studies.

Historical details

Status
Closed
Deadline
July 25, 2026
First captured
July 16, 2026
Publisher reference
0bcdbebf6ffc4be299a63e6ac5baa36f

Free. One email, sent if this program reopens or Funding Landscape first discovers a close match that is currently open. We watch for 12 months, then stop. No list.

Refine this search